In a previous report (1), we have described studies dealing with the experimental induction in man of sensitivity to leucine hypoglycemia. In healthy subjects, marked sensitivity to leucine hypoglycemia was consistently induced by prior administration of sulfonylureas, compounds that are known to stimulate islet-cell activity. On the other hand, after pretreatment with Novo Ultralente insulin, administration of leucine produced decreases in blood glucose levels that, although significant, were small and inconsistent. A modest but significant hypoglycemic effect was also produced in some healthy subjects by administering leucine without prior administration of hypoglycemic agents ( 1, 2). The magnitude of these decreases in blood glucose levels was similar to that observed after administration of leucine to subjects pretreated with Ultralente insulin. From the results of these studies, we concluded that in man release of additional insulin is the primary mechanism by which leucine decreases the blood sugar in experimentally induced sensitivity to leucine hypoglycemia. Earlier reports had demonstrated an increase in concentration of plasma insulin during leucine-induced hypoglycemia, both in infants with idiopathic hypoglycemia (3-5) and in patients with islet-cell tumors (1, 6-8).The present study, employing an immunoassay for insulin, was undertaken to determine the relationship between endogenous insulin and the induction of experimentally induced leucine hypo-* Presented in part before the 44th annual meeting of the Endocrine Society, Chicago, Ill., June 21-23, 1962. This work was supported in part by U. S. Public Health Service grants AM 02244, AM 00888, and 2A-5001, National Institute of Arthritis and Metabolic Diseases, Bethesda, Md. glycemia in man. The results indicate 1) that significant and consistent increases in peripheral plasma levels of insulin precede and accompany experimentally induced leucine hypoglycemia and 2) that release of additional insulin is the mechanism by which leucine causes hypoglycemia.
METHODSDetails of testing procedures, analytical methods, and methods of pretreatment with sulfonylurea compounds or Ultralente insulin have been described previously (1). i-Leucine 1 (0.2 g per kg body wt) was administered either orally as a suspension or intravenously as a solution. Control tests consisted of oral administration of an equal volume of tap water or iv administration of an equal volume of normal saline. Samples of peripheral venous blood were usually obtained for determination of blood glucose and plasma insulin 30 minutes before administration of the test material and at appropriate intervals for 21 to 31 hours. Blood samples for immunoassay of insulin, with a small amount of powdered heparin added, were kept chilled before centrifugation at 4°C. Subsequently the plasma was separated and stored frozen. Radioimmunoassay was usually performed several days to several weeks after the testing procedure. Samples for one test [J.S. (a), Table I] were assayed 10 months after the experiment...